Coya Therapeutics' (COYA) "Buy" Rating Reiterated at D. Boral Capital

Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at D. Boral Capital in a report issued on Thursday,Benzinga reports. They currently have a $18.00 target price on the stock. D. Boral Capital's target price would indicate a potential upside of 173.76% from the stock's previous close.

Several other analysts have also recently weighed in on the stock. Lake Street Capital started coverage on shares of Coya Therapeutics in a research note on Wednesday, July 9th. They issued a "buy" rating and a $16.00 price objective on the stock. HC Wainwright reissued a "buy" rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research note on Monday, June 9th. Wall Street Zen cut shares of Coya Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Finally, Chardan Capital reissued a "buy" rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research note on Tuesday, July 1st. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $16.50.

Coya Therapeutics Stock Up 8.3%

Shares of NASDAQ COYA traded up $0.51 during midday trading on Thursday, reaching $6.58. 112,031 shares of the company were exchanged, compared to its average volume of 76,125. The stock's 50-day moving average price is $5.79 and its 200-day moving average price is $6.03. The stock has a market cap of $109.97 million, a P/E ratio of -6.15 and a beta of 0.26. Coya Therapeutics has a one year low of $4.65 and a one year high of $10.24.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.44) earnings per share for the quarter, hitting the consensus estimate of ($0.44). The business had revenue of $257.88 million during the quarter, compared to the consensus estimate of $2.63 million. On average, equities research analysts anticipate that Coya Therapeutics will post -1.15 EPS for the current year.

Institutional Trading of Coya Therapeutics

A number of institutional investors have recently bought and sold shares of COYA. Tower Research Capital LLC TRC boosted its position in Coya Therapeutics by 1,005.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company's stock valued at $30,000 after acquiring an additional 4,777 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Coya Therapeutics during the fourth quarter valued at about $59,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Coya Therapeutics during the first quarter valued at about $65,000. Jane Street Group LLC acquired a new position in shares of Coya Therapeutics during the fourth quarter valued at about $74,000. Finally, Northern Trust Corp raised its holdings in shares of Coya Therapeutics by 12.2% during the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company's stock valued at $164,000 after purchasing an additional 3,099 shares during the period. Institutional investors own 39.75% of the company's stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.